ALB and neoplasm: Based on the findings of Neri’s group [128], Müller et al. introduced the albumin binder 4-(p-iodophenyl)butyric acid (Figure 6) to prolong the circulation time of their 177Lu-labeled folate analogue in order to achieve a better tumor-to-kidney ratio.